Skip to content
Calculator
Evidence: MediumPeptideIn Clinical TrialsRGD peptideInvestigational · phase 3 failedGlioblastoma

Cilengitide

An integrin-blocking peptide that failed in glioblastoma

Cilengitide is an arginine-glycine-aspartic acid (RGD) peptide that blocks alphavbeta3 and alphavbeta5 integrins, which help tumours grow blood vessels and invade. Promising early trials in glioblastoma led to the phase 3 CENTRIC trial, where median survival was 26.3 months with and without it.

Used in human trials: 2,000 mg, Twice weekly, Intravenous (Trial: CENTRIC (methylated MGMT glioblastoma)) Details ↓

Overview

What is it?

Integrins alphavbeta3 and alphavbeta5 regulate angiogenesis and invasiveness in cancer, and cilengitide was designed as an integrin-targeting arginine-glycine-aspartic acid (RGD) peptide to block them. In preclinical glioblastoma models it was active and worked with radiotherapy, and early clinical trials found it well tolerated with signs of activity, which led to a planned phase 3 trial.

In recurrent glioblastoma, a randomised phase 2 trial of 81 patients found an excellent safety profile and more activity at the higher dose (6-month progression-free survival 15%, median survival 9.9 months). In newly diagnosed disease, a phase 2 trial in patients without MGMT promoter methylation reported median survival of 16.3 months with the standard cilengitide regimen against 13.4 months for controls.

The decisive test was CENTRIC: 545 patients with methylated MGMT promoter tumours were randomised to standard treatment with or without cilengitide. Median overall survival was 26.3 months in both groups (hazard ratio 1.02), and no subgroup benefited. Later biomarker work confirmed that both CENTRIC and CORE missed their primary endpoints. Cilengitide was not approved.

Later work found the same pattern of near misses: a phase II combination in unmethylated glioblastoma fell short of its survival target, and a re-read of CENTRIC scans showed cilengitide more often caused imaging changes that mimicked progression. Outside the brain, CERTO added cilengitide to cetuximab and chemotherapy in advanced lung cancer; progression-free and overall survival leaned its way but missed significance.

Pharmacologically it is simple: given intravenously, about four-fifths of the dose leaves unchanged in urine, with no circulating metabolites. Combination phase 1 studies kept the 2,000 mg twice-weekly dose. Single exceptional responses exist, such as a woman in CENTRIC with no recurrence after ten years, and laboratory work keeps proposing who might respond, but in CENTRIC no subgroup benefited.

26.3 mo
Median survival in CENTRIC, both arms
hazard ratio 1.02 · PMID 25163906
2,000 mg
Dose, twice weekly IV
CENTRIC and CORE · PMID 25163906
~79%
Excreted in urine
mostly unchanged · PMID 25683324
Science

Mechanism of Action

Cilengitide is an RGD peptide designed to block the alphavbeta3 and alphavbeta5 integrins involved in angiogenesis and tumour invasion.

🧲

Integrin blockade

It was designed to block alphavbeta3 and alphavbeta5 integrins by mimicking their arginine-glycine-aspartic acid binding motif.

🩸

Angiogenesis

Blocking these integrins was meant to cut tumour blood supply and invasion, which worked in preclinical glioblastoma models.

🧪

Simple clearance

It is cleared mainly unchanged in urine, with no circulating metabolites.

Evidence

Published Research

Studies of cilengitide, from their PubMed abstracts.

Human2014

CENTRIC phase 3

In 545 patients with MGMT-methylated glioblastoma, median overall survival was 26.3 months with cilengitide and 26.3 months without (hazard ratio 1.02, p = 0.86); no subgroup benefited and no additional toxicity was seen.

PMID: 25163906
Human2015

CORE: unmethylated tumours

Median overall survival was 16.3 months with standard cilengitide (HR 0.686, p = 0.032) and 14.5 months with intensive cilengitide against 13.4 months for controls; cilengitide was well tolerated.

PMID: 25762461
Human2008

Recurrent glioblastoma phase 2

In 81 patients, cilengitide had an excellent safety profile; activity trended better at 2,000 mg, with 6-month progression-free survival of 15% and median survival of 9.9 months.

PMID: 18981465
Human2016

Biomarkers after CENTRIC and CORE

In the two failed phase 3 trials, integrin biomarkers did not predict benefit in CENTRIC; in CORE, higher tumour αvβ3 levels were associated with longer progression-free and overall survival on cilengitide.

PMID: 26918452
Human2016

With metronomic chemotherapy

In 29 patients with newly diagnosed unmethylated glioblastoma, cilengitide 2,000 mg twice weekly with metronomic temozolomide and procarbazine gave 12-month survival of 55%, short of the 65% target; median survival was 14.5 months.

PMID: 26935578
Human2024

Scans that mimic progression

Among 424 evaluable CENTRIC patients, treatment-related imaging changes that looked like progression were more common with cilengitide than without (24% against 17%), mostly in the first months after radiotherapy.

PMID: 38219019
Human2018

Lung cancer with chemoradiotherapy

In a phase I study of 14 patients with stage III non-small-cell lung cancer, continuous cilengitide infusion with chemoradiotherapy produced one dose-limiting toxicity (a tracheobronchial fistula at 40 mg/h); median progression-free survival was 14.4 months, uncontrolled.

PMID: 29221762
Human2015

Lung cancer with cetuximab (CERTO)

In 169 patients with advanced non-small-cell lung cancer, adding cilengitide to cetuximab and platinum chemotherapy gave progression-free survival of 6.2 against 5.0 months (P = 0.085) and median survival of 13.6 against 9.7 months, not significant; side effects were similar.

PMID: 25939894
Human2015

With cediranib in recurrent glioblastoma

In 45 patients, cediranib 30 mg daily with cilengitide 2,000 mg twice weekly caused no dose-limiting toxicity, but median survival was 6.5 months and 6-month progression-free survival 4.4%.

PMID: 26008604
Human2017

With paclitaxel in solid tumours

In a phase 1 study of 12 evaluable patients, cilengitide with weekly paclitaxel was tolerated, with one partial response; the recommended dose was 2,000 mg twice weekly.

PMID: 28477227
Human2015

How the body clears it

After intravenous radiolabelled cilengitide, about 79% of the dose was excreted in urine, 77.5% unchanged, with no circulating metabolites; two minor metabolites appeared in faeces.

PMID: 25683324
Human2023

A 10-year survivor

A 77-year-old woman with MGMT-methylated glioblastoma treated in CENTRIC continued cilengitide until 2016 and had no radiographic recurrence more than 10 years after diagnosis.

PMID: 37092563
Human2017

Ex vivo response in head and neck cancer

An ex vivo assay found only a subgroup of head and neck cancers responded to cilengitide-containing combinations, and that response classified patient outcome.

PMID: 28872582
Review2008

Why it looked promising

Cilengitide was active and synergised with radiotherapy in preclinical glioblastoma models, showed antitumour benefit with minimal toxicity in recurrent disease, and encouraging single-arm results led to a phase 3 trial.

PMID: 18616418
In Vitro2024

Integrin levels predict sensitivity

In breast cancer cell lines, high overall integrin levels predicted resistance to cilengitide, while low-integrin luminal lines were all sensitive.

PMID: 39707454
Animal2022

With anti-PD-1 in melanoma

In mice, cilengitide lowered PD-L1 in melanoma and, combined with an anti-PD-1 antibody, reduced tumour growth and extended survival.

PMID: 35142593
Dosing

Dosing Data

Never approved. The phase 3 glioblastoma trials gave 2,000 mg intravenously twice weekly with chemoradiotherapy.

Investigational and never approved; trial doses only.
ProtocolDoseFrequencyDurationRoute
Trial: CENTRIC (methylated MGMT glioblastoma) Human studyPMID 251639062,000 mgTwice weeklyWith temozolomide chemoradiotherapyIntravenous
Trial: CORE intensive arm (unmethylated MGMT) Human studyPMID 257624612,000 mg5 times weekly in weeks 1 to 6, then twice weeklyWith chemoradiotherapy and maintenanceIntravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

A fixed IV dose
Cilengitide was given as a fixed 2,000 mg intravenous dose in trials; it is not available.
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no regulator's label that says in what form Cilengitide is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.

Mixing a vial: a worked example

Nothing to mix at home, and no syringe units to work out: Cilengitide is prepared and given by clinical staff, by a cancer team in hospital.

In the carded trials it was infused into a vein alongside radiotherapy and chemotherapy for glioblastoma.

Source: PMID 25163906 and PMID 25762461 (studies carded under Research below).

Storage before and after mixing

Unknown: no label on file says how Cilengitide is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.

How it is taken

As it was given in human studies: Intravenous (Twice weekly; Trial: CENTRIC (methylated MGMT glioblastoma)).

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Trial: CENTRIC (methylated MGMT glioblastoma): With temozolomide chemoradiotherapy; Trial: CORE intensive arm (unmethylated MGMT): With chemoradiotherapy and maintenance.

When effects appear: unknown; no source on this page gives a time to effect for Cilengitide. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: No additional toxicity over standard treatment in CENTRIC; Lymphopenia and thrombocytopenia occurred in both arms. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Cilengitide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the trials above”).

Interactions

Unknown: a PubMed search for human interaction studies of Cilengitide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Cilengitide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: In Clinical Trials (Not approved anywhere). Sport: Prohibited (S0 catch-all).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the trials above.

● No additional toxicity over standard treatment in CENTRIC
● Lymphopenia and thrombocytopenia occurred in both arms

Contraindications & Cautions

No label; it is investigational.

● Not approved for any use
Questions

Frequently Asked Questions

?What is cilengitide?

An investigational RGD peptide that blocks alphavbeta3 and alphavbeta5 integrins, developed as a treatment for glioblastoma.

?Why did cilengitide fail?

In the phase 3 CENTRIC trial, median survival was 26.3 months with or without it, and no subgroup benefited, despite encouraging earlier phase 2 results.

?Is cilengitide available?

No. It was never approved, and anything sold under its name is an unverified research chemical.

?Was cilengitide safe?

Yes, in the trials: the recurrent glioblastoma phase 2 study reported no significant reproducible toxicities, and CENTRIC found no overall additional toxic effects over standard treatment; lymphopenia and thrombocytopenia occurred in both arms.

?Did any trial show a survival benefit?

The phase 2 CORE trial in unmethylated tumours reported 16.3 months with the standard cilengitide regimen against 13.4 months for controls, but the trial missed its primary endpoint and the larger CENTRIC trial found no benefit.

?Which patients were in CENTRIC?

Of 3,471 patients screened, 926 had a methylated MGMT promoter and 545 were randomised to standard radiotherapy and temozolomide with or without cilengitide.

?Was cilengitide tried outside glioblastoma?

Yes. In advanced non-small-cell lung cancer, CERTO added it to cetuximab and chemotherapy; survival trends favoured it but were not significant. Phase 1 combinations in other solid tumours showed occasional responses.

?How is cilengitide eliminated?

Mostly unchanged in urine: about 79% of an intravenous dose was recovered in urine and 77.5% as unchanged drug, with no circulating metabolites.

Bibliography

References

  1. [clinical-trial] Stupp R, et al. "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial." Lancet Oncol, 2014;15(10):1100-8. PMID: 25163906.
  2. [clinical-trial] Nabors LB, et al. "Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study." Neuro Oncol, 2015;17(5):708-17. PMID: 25762461.
  3. [clinical-trial] Reardon DA, et al. "Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme." J Clin Oncol, 2008;26(34):5610-7. PMID: 18981465.
  4. [pubmed] Weller M, et al. "Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome." Oncotarget, 2016;7(12):15018-32. PMID: 26918452.
  5. [pubmed] Reardon DA, et al. "Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme." Expert Opin Investig Drugs, 2008;17(8):1225-35. PMID: 18616418.
  6. [clinical-trial] Khasraw M, et al. "Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial." J Neurooncol, 2016;128(1):163-171. PMID: 26935578.
  7. [pubmed] Flies CM, et al. "Treatment-associated imaging changes in newly diagnosed MGMT promoter-methylated glioblastoma undergoing chemoradiation with or without cilengitide." Neuro Oncol, 2024;26(5):902-910. PMID: 38219019.
  8. [clinical-trial] Massabeau C, et al. "Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study." Clin Lung Cancer, 2018;19(3):e277-e285. PMID: 29221762.
  9. [pubmed] Vansteenkiste J, et al. "Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)." Ann Oncol, 2015;26(8):1734-40. PMID: 25939894.
  10. [pubmed] Gerstner ER, et al. "A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma." Neuro Oncol, 2015;17(10):1386-92. PMID: 26008604.
  11. [pubmed] Haddad T, et al. "A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors." Cancer Chemother Pharmacol, 2017;79(6):1221-1227. PMID: 28477227.
  12. [pubmed] Becker A, et al. "Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans." J Clin Pharmacol, 2015;55(7):815-24. PMID: 25683324.
  13. [pubmed] Alalami H, et al. "Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report." CNS Oncol, 2023;12(2):CNS96. PMID: 37092563.
  14. [pubmed] Cedra S, et al. "Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients." Cancers (Basel), 2017;9(9). PMID: 28872582.
  15. [pubmed] Girnius N, et al. "Cilengitide sensitivity is predicted by overall integrin expression in breast cancer." Breast Cancer Res, 2024;26(1):187. PMID: 39707454.
  16. [pubmed] Pan X, et al. "Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model." Bioengineered, 2022;13(2):4557-4572. PMID: 35142593.

Sources & Citations

Studies were read from their PubMed abstracts. Read October 7, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03